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Abstract: 
DA closure is crucial for the transition from fetal to neonatal life. This closure is supported by 
changes to the DA’s signaling and structural properties that distinguish it from neighboring 
vessels. Examining transcriptional differences between these vessels is key to identifying genes 
or pathways responsible for DA closure. Several microarray studies have explored the DA 
transcriptome in animal models but varied experimental designs have led to conflicting results. 
Thorough transcriptomic analysis of the human DA has yet to be performed. A clear picture of 
the DA transcriptome is key to guiding future research endeavors, both to allow more targeted 
treatments in the clinical setting, and to understand the basic biology of DA function. In this 
review, we use a cross-species cross-platform analysis to consider all available published 
rodent microarray data and novel human RNAseq data in order to provide high priority 
candidate genes for consideration in future DA studies. 
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Abbreviations:  
Ao: Aorta 
DEG: Differentially Expressed Gene 
bioDBnet: biological Database network 
BP: Biological Process 
CC: Cellular Component 
DAVID: Database for Annotation, Visualization, and Integrated Discovery 
ECM: extracellular matrix 
FDR: False Discovery Rate 
FPKM: Fragments Per Kilobase of transcript per Million mapped reads 
GO: Gene Ontology 
GEO: Gene Expression Omnibus 
hg38: human genome version 38 
RMA: Robust Multi-Array 
KEGG: Kyoto Encyclopedia of Genes and Genomes 
MF: Molecular Function 
UP: UniProt 
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Introduction 
The ductus arteriosus (DA) is an essential vascular shunt connecting the pulmonary 
artery and aorta, allowing oxygenated blood from the placenta to bypass the developing lungs in 
utero. After birth, DA closure is required for a proper transition to neonatal life. Often, the 
postnatal DA fails to close, resulting in persistent patency of the ductus arteriosus (PDA). PDA 
accounts for nearly 10% of congenital heart defects1,2, including more than 30% of preterm 
infants with a birth weight of <1500g3,4.    
Effective DA closure is dependent on a combination of signaling and structural changes 
which support constriction and eventual remodeling of the vessel5-7. Despite the proximity and 
common neural crest lineage of their smooth muscle cells8, the ascending aorta (Ao) doesn’t 
undergo these changes, suggesting transcriptional differences between these vessels may 
define the DA’s function. Numerous attempts to understand these differences at the 
transcriptome level have provided insight, but varied experimental design and statistical 
analyses have created contradictions and ambiguity in the literature. Further, the transcriptome 
of the human DA has not been explored with the advanced genomic techniques now available, 
such as RNA-seq. A clear picture of the DA’s transcriptional profile is key to guiding future 
research endeavors, both to allow more targeted treatments in the clinical setting, and to 
understand the basic biology underlying DA function. 
The goals of this study were to: 1) define differentially expressed genes (DEGs) in DA 
versus Ao samples that were commonly identified in previously published microarray datasets 
using rodent models, 2) identify human DA-enriched transcripts using RNA-seq analysis, and 3) 
explore transcriptional commonalities between the rodent and human DA. Although cross-
species and cross-platform comparisons are fraught with limitations, identification of robust 
markers of DA identity or novel DA-enriched pathways promises to provide unique insights into 
DA development and function. 
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Methods 
Microarray Meta-Analysis: 
Microarray data were obtained from NCBI’s Gene Expression Omnibus (GEO) database 
(Table 1). All available studies were considered, but only investigations that included a DA/Ao 
comparison were selected for analysis. For the array data from Bokenkamp et al.9, values for 
E21 laser micro-dissected endothelium and smooth muscle cells were pooled. For the array 
data from Hseih et al.10, only the F344 control samples were considered. CEL files of selected 
data sets were evaluated in Partek Genomics Suite version 7.17.1222 (Partek Inc.). All data 
were normalized using the Robust Multi-Array (RMA) method. One-way ANOVA was used to 
analyze contrasts of interest, namely vessel type, to generate lists of DEGs between DA and 
Ao. Permissive DEG lists (fold change ≥1.2) were then separated by increased or decreased 
DA/Ao expression to generate UP and DOWN lists respectively. A naïve vote counting strategy 
was used to evaluate consistency between studies. Shared genes between UP lists or DOWN 
lists from each study were determined using Partek Genomics Suite. 
RNA-seq Analysis: 
Previable (21 - 21 5/7 weeks gestation) tissue samples for human RNA-seq analysis 
were obtained as previously described11. Tissues were homogenized in Trizol with the IKA T10 
basic Ultra-Turrax. Total RNA was isolated using the RNeasy Mini kit (Qiagen). RNA quality was 
assessed using the Agilent 2100 Bioanalyzer. RNA samples with RIN score ≥6.5 were 
considered for further study. 1 microgram of total RNA was used for library construction using 
the ScriptSeq Complete Gold Kit (Illumina). The libraries, four biological replicates per vessel 
type, were sequenced on an Illumina HiSeq 2000 by 100bp pair-end sequencing. RNA-seq data 
was uploaded to Partek Flow (Partek Inc.). Trimming of raw reads (both ends) was based on a 
minimum read length of 25 and discarded bases after 85. Trimmed reads were aligned to 
Human Genome Version 38 (hg38) using STAR – 2.5.3a and quantified to Refseq Transcripts 
83 using Partek’s E/M method. Aligned counts were FPKM normalized with an offset of 1. Gene 
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specific analysis (GSA) was used to detect DA vs. Ao DEGs. DEGs with an FDR of ≤0.1 and a 
fold change ≥2 were considered significant. Volcano plot and dendogram heat map figures were 
generated using Partek Flow. 
Comparison of Microarray and RNA-seq DEGs: 
Rodent gene symbols were converted to human orthologues using biological Database 
network (bioDBnet) to identify genes common between microarray and RNA-seq DEG lists. 
Lists were manually aligned to determine genes differentially expressed in both microarray and 
RNA-seq analyses. Microarray and RNA-seq gene lists were submitted independently for 
functional annotation using the Database for Annotation, Visualization, and Integrated Discovery 
(DAVID). Functional terms from Gene Ontology (GO) Biological Process (BP), GO Cellular 
Component (CC), GO Molecular Function (MF), Kyoto Encyclopedia of Genes and Genomes 
(KEGG), and UniProt (UP) Keywords databases were evaluated for similarities. Lists of 
functional terms and keywords from each database were then manually aligned. In order to 
create comparison diagrams, significant terms (p≤0.05) were chosen based on count (defined 
as number of genes identified in each term), and ordered by –Log(p value). 
 
Results 
Comparison of Published Rodent Microarrays 
Our microarray meta-analysis focused on studies containing DA to Ao comparisons in 
term animals, since there were too few preterm studies for comparison. Comparison of DA to Ao 
expression allowed DA-specific genes to be distinguished from temporally-regulated genes that 
are important for generalized vessel development. Differential expression was recalculated from 
raw data using a uniform statistical approach. Array data from three mammalian species (rat, 
mouse, sheep) were available, but differences in experimental design and genome annotation 
limited the use of data from sheep12. Four rodent studies met pre-specified criteria (vessel type, 
gestational stage) and were included for analysis9,10,13,14 (Table 1). There were 444 genes 
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identified as differentially expressed in at least three of four arrays. Of these, 87 genes were 
consistently increased in DA versus Ao (DA enriched), while 189 genes were consistently 
decreased in DA versus Ao (Ao enriched) (Figure 1). Complete gene lists are provided for both 
DA enriched (Table S1) and Ao enriched (Table S2) gene sets. Interestingly, many of the genes 
that were common to at least 3 studies, such as Abcc911,15-17, Cacna1c18, Edn111,13,19, 
Pde4b12,20, Ptger411,21-26, and Tfap2b11,27-33, have previously been identified as significant for DA 
function (Table S1, blue typeface). A more thorough listing of previously identified genes 
significant for DA function can be found in Lewis et al.34. Identification of these established 
genes suggests that this approach was sufficient to detect genes and pathways relevant for DA 
function. 
Human RNA-seq Analysis 
cDNA libraries were prepared for paired DA and Ao samples from 4 subjects. Libraries 
were sequenced to an average of 60 million genomic reads with an average genomic coverage 
rate of 67.7% (Table 2). Reads were aligned to human genome version 38 and quantified 
against Refseq Transcripts 83. GSA was then used to detect DEGs from counts normalized to 
Fragments Per Kilobase of transcript per Million (FPKM)-mapped reads. Hierarchical clustering 
analysis resulted in a heat map of RNA-seq samples (Figure 2). This heat map demonstrates 
that vessel identity was the primary determinant of clustered expression patterns. Interestingly, 
77% of probes selected for hierarchical clustering were DA enriched, compared to 23% Ao 
enriched, suggesting the DA’s phenotype is driven by expression of DA-specific genes, as 
opposed to suppression of Ao-specific genes. Overall, 2082 genes showed differential 
expression between DA and Ao with a p-value of 0.05 and fold change of ≥2 (Figure 3). 186 of 
these genes met a permissive FDR criteria (Benjamini-Hochberg) of 0.10 or less, with 118 
showing increased expression in the DA compared to Ao and 68 showing decreased expression 
in DA compared to Ao. Complete gene lists from this analysis are provided for both DA enriched 
(Table S4) and Ao enriched (Table S5) transcripts. The 20 most highly expressed (by FPKM) 
DEGs in the human DA were also identified (Table S6).  
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Intersection of Human and Rodent DEGs 
To compare the findings of the microarray and RNA-seq studies, rodent gene symbols 
were converted to human orthologues (bioDBnet). Of the 276 DEGs from the rodent microarray 
analysis and the 186 DEGs from the human RNA-seq, 11 genes were common to both studies 
(Figure 4). Several of these genes, including ABCC911,15-17, PDE1C11,20,35, PTGER411,21-26, and 
TFAP2B11,27-33 have previously been described as significant for DA identity. TFAP2B had a 
notably high fold change (37.9) similar to findings from individual microarray studies (Table S1) 
Genes differentially expressed between DA and Ao were categorized by functional 
annotation (DAVID). Overlap between rodent microarray and human RNA-seq was found for 
GO Biological Process (48.4%), GO Cellular Component (63.2%), GO Molecular Function 
(47.4%), KEGG (55.6%), and UniProt (UP) Keywords (59.5%) (Table S7). Of the top 30 UP 
Keyword terms from rodent microarray and human RNA-seq, 16 were found in common (Figure 
5). Terms such as ‘Calcium’, ‘Cell adhesion’, ‘collagen’, ‘extracellular matrix’, and 
‘metalloprotease’ align with pathways known to be important for DA constriction and 
remodeling5,30,36-41. 
 
Discussion 
There are currently nine published microarray studies of the DA9,10,12-14,26,42-44, each 
performed to answer a specific question, and consequently, each with a different experimental 
design. In order to extract the most meaningful information from these studies, criteria were 
selected that would include as many studies as possible while only considering comparable 
data sets. We focused on studies that included DA to Ao comparisons as they distinguish 
between DA-specific genes and developmental genes also expressed in neighboring 
vasculature, while also controlling for biases inherent to each study. In addition, studies that 
analyzed the term-gestation time point were chosen because this developmental time point was 
the most represented among available microarray data sets. Although individual array studies 
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have identified differences between term and preterm DAs9,12,13, examination of the available 
data suggested that differences in study design and consideration of disparate preterm time 
points would make data alignment unreliable and preclude inter-study comparisons. There is 
one published microarray study of human DA samples, though it was not considered because it 
was conducted on abnormal tissue (patients requiring DA stents) and contained no Ao tissue for 
comparison45. Overall, 11 genes were differentially expressed in both the preterm human RNA-
seq as well as the term rodent microarrays, suggesting that a small subset of genes may define 
DA identity over a broad developmental time span and between species. This number would be 
expected to increase in an analysis comparing differential time points in the same species or 
comparable time points across different species. 
Among the DEGs identified as common between rodent microarray data sets and 
human RNA-seq analysis were several genes which have been previously identified as 
important for the DA. Two of these, PTGER4, which encodes the prostanoid receptor EP4, and 
TFAP2B, which encodes transcription factor AP-2β, have key roles in DA biology. EP4 is a G-
protein coupled receptor and primary regulator of DA patency. EP4 is the predominant 
prostanoid receptor in the mammalian DA46-54. During late gestation, circulating prostaglandin E2 
(PGE2) stimulates EP4 to maintain DA patency
48-50. Catabolism of circulating prostaglandins by 
15-hydroxy-prostaglandin dehydrogenase in the newly inflated lungs helps facilitate neonatal 
DA closure55,56. Interestingly, EP4 knockout mice die shortly after birth with a PDA
21-25. Similarly, 
mice lacking both of the cyclooxygenase enzymes required for PGE2 production, also die with 
PDA57,58. Normally the removal of a dilatory stimulus would be expected to result in constriction, 
but these animals paradoxically present with a widely patent DA. Taken together, these findings 
suggest that prostaglandins, acting via the EP4 receptor pathway, may play a role in 
developmentally programming the DA in addition to their acute vasodilatory function21,26,57,59,60. 
The prevalence of EP4 among microarray studies and its high fold change in our human RNA-
seq data support its role as an important regulator of DA development and function. 
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TFAP2B is thought to regulate proliferation and differentiation during development. 
Mutations in TFAP2B result in Char syndrome, a neural crest disorder typically associated with 
developmental abnormalities of the hands and face, as well as PDA27,29,32. Single nucleotide 
variants in TFAP2B have also been linked to non-syndromic PDA31,33. TFAP2B was highly 
enriched in DA vs. Ao expression in both human RNA-seq (38-fold increase) and three rodent 
microarrays (33-fold increase in Shelton et al.14). Tfap2b was not included in the probe set used 
by Jin et al., and thus was found significant in all possible sources. Interestingly, the array from 
Bokenkamp et al.9 found Tfap2b to be similarly enriched in both DA SMC and DA endothelium, 
despite only DA SMCs originating from the neural crest61. These findings are consistent with 
previous speculation that Tfap2b may act as a critical regulator of DA gene expression. Ivey et 
al. showed that Tfap2b expression was specific to DA SMCs and that knockout mice lacked 
proper SMC differentiation62. They also found that Tfap2b expression was required for the 
sequential expression of hypoxia inducible factor 2α (Hif2a) and endothelin-1 (Et-1). These data 
suggested the hypothesis that Tfap2b is a transcriptional regulator which interacts with Hif2a 
and Et-1 during development to drive differentiation of DA SMCs. In order to determine the true 
role of Tfap2b in DA development, transcriptional comparisons must be made between the DA 
of Tfap2b null and wild-type mice. 
Of the eleven DEGs common to the human RNA-seq and rodent microarrays, one gene, 
phosphodiesterase 1C, (PDE1C) showed discordant results for DA vs. Ao expression between 
species. Pde1c had consistently decreased DA/Ao expression in three rodent microarray 
studies (-1.3, -2.4, and -2.9 fold change), but increased DA/Ao expression in human RNA-seq 
data (33.2 fold change). PDE1C catalyzes hydrolysis of the second messengers, cAMP and 
cGMP. Given the importance of both EP4 and nitric oxide signaling via cAMP and cGMP, 
respectively, in regulating DA tone60,63-65, PDE1C’s involvement in the DA is logical. PDE1C 
activity has been shown to affect DA tone66-68 and is thought to do this by attenuating the 
dilatory effects of EP4 stimulation and downstream cAMP production in the DA
20. PDE1C is also 
associated with pathological vascular remodeling, driving proliferation and migration in vascular 
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smooth muscle cells, processes relevant for DA functionality69,70. Due to this study’s limitations, 
it is unclear whether this discrepancy arises from gestational differences, species differences, or 
some unknown experimental factor. 
Similarly, some genes shown to be relevant for DA function in prior studies were not 
identified in our combined approach. For example, KCNMA1, which encodes a subunit of the 
BKCA potassium channel, was identified in the microarray study by Shelton et al.
14 as enriched in 
the DA (fold change 2.1). Those results were confirmed by RT-qPCR, in situ hybridization and 
functional analysis14. Despite these convincing results, KCNMA1 was enriched in the Ao by 
other microarrays and our human RNA-seq data. Considering Shelton et al. is the only study 
using mice, this may represent a species-specific difference. These findings highlight the 
importance of multi-model comparisons in DA research. 
There are several limitations in our present analysis. Previous DA microarray studies 
have raised concerns about the efficacy and appropriateness of directly comparing different 
microarray data sets9,12,71,72. This is not field-specific, and there are well-known limitations to this 
type of comparison73-75. This is especially true for embryonic and pregnancy-associated tissues 
which have high internal variability even within tissue type76,77. The primary concern is a bias 
towards type 2 errors, or under-detection of truly differentially expressed and biologically 
relevant genes.  
Direct gene comparison between species also suffers from differences in naming 
conventions and conservation of specific orthologues. To address this, we focused on functional 
annotation of our gene lists, to emphasize pathways that were in agreement rather than 
individual gene identity. This strategy has been shown to be more consistent across studies and 
yield more reproducible, biologically informative results75,78. In doing so, several aspects of 
vessel physiology which may be altered between the DA and neighboring vessels were 
identified. Genes associated with alterations in extracellular matrix (ECM) organization between 
DA and Ao were identified by GO biological process, GO cellular component, GO molecular 
function, and UP keywords in both rodent microarrays and human RNA-seq. Alterations in ECM 
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composition play a critical role in remodeling of the DA in both late gestation and neonatal 
life5,30,36,39,40. Interestingly, several mouse knockout models of ECM-related genes have 
PDA79,80. There was limited direct alignment of ECM-associated genes between the microarray 
and RNA-seq studies. Only periostin (POSTN), an integrin binding protein which supports cell 
adhesion and migration, was identified in both rodent microarrays and human RNA-seq. 
However, both rodent arrays and human RNA-seq studies identified several collagen family 
members (Col11a1, Col3a1, Col5a2, Col6a3) (COL8A1, COL8A2, COL9A1, COL19A1) and 
ADAMTS family genes (Adamts1, Adamts9, Adamtsl2, Adam33, Adamtsl5) (ADAMTS9, 
ADAMT22, ADMATS8). These data suggest that though there are species differences in 
orthologues, similar pathways are important for both the rodent and human DA.  
This study was also hindered by the limited number of preterm datasets. Because the 
human RNA-seq and rodent microarray data were obtained at different gestational time points, it 
is difficult to draw clear, unbiased comparisons. Ambiguity still exists concerning the correlation 
of critical events in DA development between rodents and humans. Thus, at this point, more 
information on developmental milestones is needed to identify parallel features of DA regulation.  
Finally, microarray studies were performed on different platforms, resulting in different 
sets of transcripts that could possibly be detected for each array. Comparisons between these 
platforms were then limited to the sets of genes that are represented on all array platforms. This 
is a minor shortcoming, but is further compounded when comparing microarray results to RNA-
seq, which is not restricted by predetermined probe sets as a sequencing-based approach. 
Thus, our list of genes common to both rodent microarrays and human RNA-seq data sets is 
capped by the set of genes which is represented on the most limited array platform, 
predisposing this analysis to under-report significant genes from the RNA-seq which may have 
been omitted from specific microarray platforms. 
 In conclusion, comparison of microarray studies from animal models with new 
information from human RNA-seq data generated high priority candidate genes to consider in 
future DA studies. Identification of DA-specific or highly enriched genes in the DA is a requisite 
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step in finding new DA-selective drugs or providing a molecular address for homing of 
therapeutic agents to the target tissue. Although cross-platform and cross-species 
transcriptomic comparisons are fraught with limitations, they offer a unique opportunity to 
visualize pathways of interest to better understand DA development and function.              
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Figure 1. Venn diagram of compared rodent microarray studies.  Darkly shaded areas 
represent 444 DEGs (p-value ≤ 0.05, fold change ≥ 1.2) identified by at least 3 of 4 studies. Of 
these, 168 genes had conflicting direction of expression and were excluded from further 
analysis. Of the remaining 276 genes, 87 were consistently increased, while 189 were 
consistently decreased in DA versus aorta (genes are listed in Tables S1 and S2, respectively). 
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Figure 2. Dendogram of Human RNA-seq samples. Heat map analysis of RNA-seq data 
showing separation of samples by vessel identity. Gene identities are specified in Tables S4, 
S5. 
 
 
 
Figure 3. Volcano plot of RNA-seq differentially expressed genes. With p-value 0.05 and 
fold change >2, 2082 genes showed differential expression in the human DA compared to aorta: 
1027 up-regulated, and 1055 down-regulated. Of these, 186 genes had an FDR (Benjamini-
Hochberg) of 0.10 or less: 118 up-regulated, and 68 down-regulated (genes are listed in Tables 
S4 and S5, respectively). 
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Figure 4. Venn diagram of DA vs. Ao genes common between Microarray and RNA-seq 
analyses. 11 genes were identified as differentially expressed between DA and aorta in both 
the human RNA-seq and the rodent microarray comparison. 186 genes from RNA-seq are listed 
in Tables S4, S5; 276 genes from microarray comparisons are listed in Tables S1, S2.     
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Figure 5. ‘Tornadogram’ showing top 30 UniProt (UP) Keywords common between 
Microarray and RNA-seq analyses.  Genes differentially expressed in DA vs. Ao were 
categorized by UP Keywords (DAVID), plotted by p-value, and compared across platforms. 
Number of genes represented in each category shown at the end of bars. 
 
 
 
